PR

ProGen, Co,, LTD.

Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.

296160 | KO

Overview

Corporate Details

ISIN(s):
KR7296160005
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172, 6층, 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ProGen is a clinical-stage biotechnology company focused on the research and development of innovative therapeutics. The company specializes in creating protein-based immunotherapies through its proprietary Neo Tri-ImmunoGlobulin (NTIG) platform, a next-generation technology for developing multi-specific fusion proteins and antibody treatments. ProGen's pipeline primarily targets metabolic diseases, immune disorders, and cancer. The company's business model is centered on platform-based drug discovery and pursuing global partnerships for late-stage clinical development and commercialization of its long-acting biologics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.8 KB
2025-08-18 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 24.2 KB
2025-08-18 00:00
Regulatory News Service
지정자문인선임계약의변경
Korean 5.1 KB
2025-07-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-07-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 99.0 KB
2025-07-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 122.5 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-11 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.7 KB
2025-06-11 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 42.2 KB
2025-06-11 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.8 KB
2025-05-28 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 43.5 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 123.5 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB

Automate Your Workflow. Get a real-time feed of all ProGen, Co,, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProGen, Co,, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProGen, Co,, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.